For more informationContact us
bioMérieux's Commitment to Public Health
Rapid testing with VIKIA® HIV and VIKIA® Malaria can have a significant impact on the fight against infectious diseases. Using a small amount of whole blood, serum or plasma, users can obtain results regardless of access to laboratory equipment or electricity with minimal training. Tests are therefore both accessible and reliable, without compromising on quality. The First Line Biology™ solutions are bioMérieux's answer and commitment to meeting the needs of public health.
All tests use the immunochromatography (lateral flow) technique and come individually wrapped in a sealed pouch.
VIKIA® HIV 1/2
The VIKIA HIV 1/2 is a First Line Biology rapid test that detects antibodies to HIV-1 and HIV-2 in human serum, plasma or whole blood.
Stable at between 4 and 30°C, and with results at 30 minutes, it is between 99.71 and 99.95% specific, and 99.59 and 99.86% sensitive, depending on the sample used.
The VIKIA® HIV 1/2 rapid test is CE-marked and prequalified by the World Health Organization (WHO)
VIKIA® Malaria Ag Pf/Pan
A valuable tool in the diagnosis of malaria, the VIKIA Malaria Ag Pf/Pan First Line Biology rapid test detects the Plasmodium antigens in human whole blood specimens, and provides a differential diagnosis of Plasmodium falciparum from other, less virulent, malaria infections.
Stable between 2 and 30°C, the assay provides results at 20 minutes. Results remain stable for another 10 minutes, for the convenience of users. VIKIA Malaria Ag Pf/Pan has been tested extensively in the field on clinical samples. Multi-centre evaluation results in two endemic countries – Cambodia and Mali – on more than 1,700 samples show high sensitivity and specificity for confident results at different levels of parasitaemia, especially for the detection of P. falciparum.
VIKIA® HBs Ag
The VIKIA HBs Ag First Line Biology rapid test detects the presence of the hepatitis B surface antigen in human serum, plasma or whole blood, during acute or chronic infection.
Stable between 4 and 30°C, the assay provides first results within 30 minutes . Test performance has been reliably proven during clinical trials on various samples from populations in Latin America, Africa, Asia and Europe.